Dr. Steven M. Altschuler has been chief executive officer of The Children’s Hospital of Philadelphia (CHOP) since 2000. Previously, Steve served in many leadership roles at CHOP including: division chief of Gastroenterology, physician-in-chief, inaugural holder of the Leonard and Madlyn Abramson Endowed Chair in Pediatrics and professor and chair of the Department of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania.
Steve’s tenure as CEO has seen the most significant growth in the Hospital’s 159-year history. Beyond its Main Campus in University City, CHOP maintains an extensive Care Network that provides primary, specialty and urgent care, and more at over 50 locations in the Philadelphia region. The Hospital’s International Medicine program—encompassing patient care, professional education and clinical partnerships—is one of the largest in the world. A respected advocate for children’s health, Steve has spearheaded innovative multi-institution efforts to better coordinate services for complex patients, thus reducing financial burden and improving care.
CHOP’s Research Institute, number one in NIH funding among pediatric institutions, has made groundbreaking advances in gene therapy, T-cell therapy for cancer and prenatal treatment of birth defects. In forming Spark Therapeutics, Steve led the creation of the Hospital’s first for-profit enterprise in gene therapy.
Steve received his B.A. in mathematics and his M.D. from Case Western Reserve University. He completed his pediatric internship and residency at Children’s Hospital Medical Center-Boston and fellowship training in gastroenterology and nutrition at The Children’s Hospital of Philadelphia and the University of Pennsylvania School of Medicine. For 15 years, Steve was a faculty member of the department of pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Steve serves on the board of directors for Mead Johnson Nutritionals, Children’s Miracle Network Hospitals, the Free Library of Philadelphia, University HealthSystem Consortium, the Healthcare Institute and the GAVI Alliance Campaign.
Arthur Dantchik is a managing director and serves on the management committee of Susquehanna International Group, LLP, a global quantitative trading firm. He has general oversight responsibilities for SIG's domestic energy and commodity trading businesses, as well as the firm's private equity group and its international trading affiliates in Dublin and Sydney. He also manages SIG's market maker training program, one of the most highly regarded curriculums on Wall Street. Arthur has over two decades experience managing derivatives and equities trading operations, including options market making on the Philadelphia Stock Exchange. He received a B.A. in biology from the State University of New York at Binghamton and attended Arizona State University for graduate study in psychology with an emphasis on decision making.
Dr. Sharad Mansukani serves as senior advisor to TPG (formerly Texas Pacific Group), a global private equity investment firm with a capital portfolio of over $55 billion focused on leveraged buy-outs, venture capital, growth capital and hedge fund investments. He serves on the board of directors of The Children's Hospital of Philadelphia (CHOP); IASIS Healthcare, a US-based 19-facility acute care hospital system; Par Pharmaceuticals (formerly NYSE:PRX), one of largest global generic pharmaceutical companies; Surgical Care Affiliates (SCA), the largest ambulatory surgery center business in the US, which operates ~160 ASCs and three surgical hospitals (formerly part of HealthSouth); and IMS Health (IMS formerly NYSE:RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries.
Previously, Sharad was appointed to Medicare's Program Advisory and Oversight Committee by the Secretary of the Department of Health and Human Services. This committee was established by Congress and is tasked to advise Medicare upon CMS payment policies. He also served as senior advisor to the administrator of the Centers for Medicare and Medicaid Services (CMS), where he advised on design and implementation of the Medicare prescription drug benefit, Medicare Part B reform and Medicare Advantage policy. His work at CMS also included improving collaboration between Medicare, the Food and Drug Administration (FDA) and the National Institutes of Health (NIH). Prior to CMS, Sharad was senior vice president and chief medical officer at Health Partners, a Medicaid and Medicare health plan owned by the Philadelphia-area medical schools. He completed a residency and fellowship in ophthalmology at the University of Pennsylvania School of Medicine, a fellowship in quality management and managed care at the Wharton School of Business and is a graduate of the managed care executive program at the Kellogg School of Business. He is also a strategic advisor to the Cigna Board of Directors and served on the board of directors for HealthSpring.
Jeffrey Marrazzo is co-founder, president and chief executive officer of Spark and serves on the board of directors. He is an experienced entrepreneur dedicated to curing disease through genomic medicine. Jeff was part of the founding management of Generation Health, a pharmacogenomics medicines company that was acquired by CVS Caremark in 2009, and a senior member of the business development and finance teams at Tengion, a venture-backed regenerative medicine company that went public in 2010. Most recently, Jeff launched the U.S. division of Molecular Health, Inc., securing capital and recruiting a management team for this emerging leader in personalized cancer therapy. Throughout his career, he has helped raise or place more than $150 million in venture capital and has led or co-led the formation of novel strategic partnerships with the FDA, Quest Diagnostics, GE Healthcare and SAP. Previously, he served as healthcare advisor to former Pennsylvania Governor Edward G. Rendell and as an IBM management consultant to global pharmaceutical companies. He has also advised investment firms such as Goldman Sachs, Safeguard Scientifics and BioAdvance. Jeff holds a dual M.B.A./M.P.A. from The Wharton School and Harvard University, a program which he founded and a B.S.E. and B.A. in systems science and engineering and economics from the University of Pennsylvania.
Dr. Elliott Sigal has over 25 years of combined experience in medicine, research and executive management. Most recently, he served as director, executive vice president and chief scientific officer and president of R&D at Bristol-Myers Squibb from 2004 until 2013. Elliott was a principal architect of the company's successful Biopharma Transformation Strategy which is fully dedicated to innovative therapies for unmet medical needs, and was instrumental in increasing R&D productivity, developing the company's strategy in biologics and acquiring external innovation in its String of Pearls initiative. Under his leadership, fourteen new medicines were brought to market. Elliott previously held positions of increasing responsibility in drug discovery at the pharmaceutical company Syntex and also was vice president of R&D and chief executive officer for the genomics firm Mercator Genetics, where he provided the research leadership that resulted in the discovery of the gene for hemochromatosis, a common disorder that leads to iron overload, diabetes and liver disease.
Elliott received his M.D. from the University of Chicago and trained in internal medicine and pulmonary medicine at the University of California, San Francisco (UCSF). He received his research training at the Cardiovascular Research Institute at UCSF and served on the faculty of the UCSF Department of Medicine. He received his B.S., M.S. and Ph.D. in industrial engineering from Purdue University. Elliott currently serves as a member of the board of directors for the Mead Johnson Nutrition Company, the Melanoma Research Alliance and the University of California San Francisco Nina Ireland Program for Lung Health.
Thomas Todorow is executive vice president for Corporate Services and chief financial officer at The Children's Hospital of Philadelphia (CHOP). As CFO of the organization since June 2001, Tom oversees Finance, Accounts Payable, Payroll, Billing Operations, Treasury, Managed Care Contracting, Supply Chain and Investments. Before joining CHOP, Tom was vice president of finance and later chief financial officer of Harvard Pilgrim Health Care. Prior to that, Tom was involved with several healthcare start-up ventures and was a vice president in JP Morgan's healthcare investment banking group. He was also assistant treasurer and controller at the Fox Chase Cancer Center. Tom spent the first five years of his career in public accounting, including three years with Laventhol and Horwath and two years as audit supervisor with Coopers & Lybrand. Tom holds a B.S. in finance and accounting from Drexel University and has an M.B.A. from the Wharton School at the University of Pennsylvania.
Dr. Rogério Vivaldi is chief executive officer and president of Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from neuropsychiatric diseases. Over the past 20 years Rogério has been involved in commercializing around 20 pharmaceutical products addressing a wide range of unmet medical needs, mainly within the Rare Diseases therapeutic area. He most recently served as senior vice president and head of the Rare Diseases business unit at Genzyme, a Sanofi company. Prior to that he led the establishment of Genzyme's business operations in Brazil and served as president of Genzyme Latin America. During his 17 year tenure at Genzyme, he spearheaded the company's patient-centric approach to product development and marketing and he has extensive experience in building relationships with government and regulatory agencies and patient advocacy organizations.
For 18 years Rogério also owned a private medical practice specializing in diabetes and endocrinology care. He received his medical degree from Rio de Janeiro University (UNIRIO) and completed his residency in metabolism and endocrinology at Rio de Janeiro State University (UERJ) and his fellowship at Mount Sinai Hospital Center in New York, Department of Genetics with an emphasis on Gaucher's disease. He completed his M.B.A. at Coppead, Rio de Janeiro Federal University (UFRJ). Rogério was the first Brazilian medical doctor to treat a patient in Brazil with enzyme replacement therapy for Gaucher's disease in 1992.